secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2026-05-14T12:06:12+00:00
Accession:  0001104659-26-060726
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx Q1 net loss $46.3M; reacquires bota-vec from J&J; raises $100M
-----------------------------------------------------------------------

- Net loss attributable to ordinary shareholders was $46.3M ($0.57 per share) for Q1 2026, vs $40.0M ($0.51) in Q1 2025.
- Cash and cash equivalents were $71.5M at March 31, 2026; subsequent $100M equity offering and $25M upfront payment to J&J for bota-vec.
- Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia; positive 3-year data from Phase 1 AQUAx study.
- Appointed Penny Fleck as Chief Development Officer; Stuart Naylor as Chief Scientific Officer, Ophthalmology.
- Reacquired full rights to bota-vec for XLRP from J&J with $25M upfront plus milestones and mid-teens royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000110465926060726/0001104659-26-060726-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000110465926060726/mgtx-20260514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-060726

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer